If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
The first reliably documented report of Psilocybe semilanceata intoxication involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's Green Park. According to the chemist Augustus Everard Brande, the father and his four children experienced typical symptoms associated with ingestion, including pupil dilation, spontaneous laughter and delirium. The identification of the species responsible was made possible by James Sowerby's 1803 book Coloured Figures of English Fungi or Mushrooms, which included a description of the fungus, then known as Agaricus glutinosus (originally described by Moses Ashley Curtis in 1780). According to German mycologist Jochen Gartz, the description of the species is "fully compatible with current knowledge about Psilocybe semilanceata." In the early 1960s, the Swiss scientist Albert Hofmann—known for the synthesis of the psychedelic drug LSD—chemically analyzed P. semilanceata fruit bodies collected in Switzerland and France by the botanist Roger Heim. Using the technique of paper chromatography, Hofmann confirmed the presence of 0.25% (by weight) psilocybin in dried samples. Their 1963 publication was the first report of psilocybin in a European mushroom species; previously, it had been known only in Psilocybe species native to Mexico, Asia and North America. This finding was confirmed in the late 1960s with specimens from Scotland and England, Czechoslovakia (1973), Germany (1977), Norway (1978), and Belgium and Finland (1984).
His form in the first half of the year before his injuries was praised within the industry, with Herald Sun journalist, Sam Landsberger, claiming he was in All-Australian form and he signed a three-year contract with the club, tying him to the club until the end of the 2017 season. He played nineteen matches for the season and finished fourth in the best and fairest count for the second consecutive season. Hibberd played every match for the 2015 season apart from the final round match against Collingwood due to a knee injury. After strong seasons in 2013 and 2014, he had a dip in form after spending more time in the midfield. Despite a drop in form, he managed a top-ten finish in the best and fairest, placing eighth and he was named in Essendon's best players six times during the season by AFL Media.
== Toxicity of UCM hydrocarbon components == There is compelling evidence that components within some UCMs are toxic to marine organisms. The clearance rate (also known as feeding feed) of mussels was reduced by 40% following exposure to a monoaromatic UCM derived from a Norwegian crude oil. The toxicity of monoaromatic UCM components was further evidenced by an elegant set of experiments using transplantations of clean and polluted mussels. Recent analysis by GC×GC-ToF-MS of UCMs extracted from the mussel tissues, has shown that they contain a vast array of both known and unknown compounds. The comparative analysis of UCMs extracted from mussels known to possess high, moderate and low Scope for Growth (SfG), a measure of the capacity for growth and reproduction, revealed that branched alkylbenzenes represented the largest structural class within the UCM of mussels with low SfG; also, branched isomers of alkyltetralins, alkylindanes and alkylindenes were prominent in the stressed mussels. Laboratory toxicity tests using both commercially available and specially synthesised compounds revealed that such branched alkylated structures were capable of producing the observed poor health of the mussels. The reversible effects observed in mussels following exposure to the UCM hydrocarbons identified to date are consistent with non-specific narcosis (also known as baseline) mode of action of toxicity. There is no evidence that toxic UCM components can biomagnify through the food chain.
For example, the Jumblatt family sponsored the building of the Maronite Church of Our Lady of Durra in Mukhtara, and the Arslan family supported construction of the Saint Michael the Archangel Orthodox Church in Choueifat. Educated generations of Maronite commoners took up positions as scribes, clerks, physicians, and household agents in the service of notables, including both Maronite and Druze feudal families, such as the Jumblatt family.
=== Priority review voucher (PRV) === The priority review voucher is a provision of the Food and Drug Administration Amendments Act of 2007, which awards a transferable "priority review voucher" to any company that obtains approval for a treatment for a neglected tropical diseases. The system was first proposed by Duke University faculty David Ridley, Henry Grabowski, and Jeffrey Moe in their 2006 Health Affairs paper: "Developing Drugs for Developing Countries". President Obama signed into law the Food and Drug Administration Safety and Innovation Act of 2012, which extended the authorization until 2017. In April 2026, the scope of the voucher system was expanded through an executive order aimed at accelerating the approval of mental health treatments that have received Breakthrough Therapy designations. This order established non-transferable National Priority Vouchers (NPV), specifically designed for psychedelic-assisted therapies and psychoplastogens.
Sources: en.wikipedia.org
Hence in each tier, pairs of genes are cloned into a destination fragment in the desired sequence, and these are subsequently assembled two at a time in successive tiers. Like MoClo, the Golden Braid standard alternates the BsaI and BpiI restriction enzymes between each tier. The development of the Golden Gate assembly methods and its variants has allowed researchers to design tool-kits to speed up the synthetic biology workflow. For example, EcoFlex was developed as a toolkit for E. Coli that uses the MoClo standard for its DNA parts, while a similar toolkit has also been developed for engineering the Chlamydomonas reinhardtii microalgae.
== See also == List of benzodiazepines Benzodiazepine dependence Benzodiazepine withdrawal syndrome Long-term effects of benzodiazepines Lofendazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Arfendazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Triflubazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) CP-1414S (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Premazepam (pyrrolodiazepine derivative and partial benzodiazepine receptor agonist) Nordazepam (1,4-benzodiazepine derivative and partial benzodiazepine receptor agonist)
== Medical uses == Alteplase is indicated for the treatment of acute ischemic stroke, acute myocardial infarction, acute massive pulmonary embolism, and blocked catheters. Similar to other thrombolytic drugs, alteplase is used to dissolve clots to restore tissue perfusion, but this can vary depending on the pathology. Generally, alteplase is delivered intravenously into the body. To treat blocked catheters, alteplase is administered directly into the catheter.
== Further reading == Cook, E.M, and DuMont, H.D. (1991) Process Drying Practice, McGraw-Hill, Inc., ISBN 0-07-012462-0 Keey, R.B., (1992). Drying of Loose and Particulate Materials 1st ed., Taylor & Francis, ISBN 0-89116-878-8 Nutritional evaluation of food processing second edition (1975), Robert S. Harris, Ph.D. and Endel Karmas Ph.D. (eds) Filková, I., & Mujumdar, A. S. (2020). Industrial spray drying systems. In Handbook of industrial drying (pp. 263-307). CRC Press. Jafari, S. M., Arpagaus, C., Cerqueira, M. A., & Samborska, K. (2021). Nano spray drying of food ingredients; materials, processing and applications. Trends in Food Science & Technology, 109, 632-646. Klimša, V., Ruphuy, G., Jonáš, J., Mašková, L., Kašpar, O., Žvátora, P., & Štěpánek, F. (2023). Spray drying robot for high-throughput combinatorial fabrication of multicomponent solid dispersions. Powder Technology, 428, 118872.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.